Brain

Creyos Recognized as Quarterfinalist for the 2025 Digital Health Hub Foundation: Digital Health Awards

TORONTO, Sept. 30, 2025 /PRNewswire/ -- Creyos, the digital platform reshaping brain health assessment in clinical care, is thrilled to announce…

4 months ago

The ADDF’s Diagnostics Accelerator Unveils SpeechDx Dataset and New Partnership to Catalyze Breakthroughs in Speech-Based Biomarkers

The gold-standard dataset will power a new generation of AI tools to forecast Alzheimer's risk, track progression, and guide interventions…

4 months ago

Neurophet Publishes Clinical Validation Results of ‘Neurophet AQUA’ in Annals Academy of Medicine Singapore

- Clinical study conducted at the Dementia Research Centre, Nanyang Technological University, Singapore, involving Southeast Asian participants - Expert level accuracy,…

4 months ago

AIML and BC Brain Wellness Program Launch Pilot to Explore the Heart–Brain Connection

Leveraging MaxYield™ ECG to capture real-world exercise data in people living with neurological conditionsGenerating actionable insights into how cardiac responses…

4 months ago

Anavex Life Sciences Announces Publication of Oral Blarcamesine Describing a New Class of Clinical Precision Medicine from Phase IIb/III Alzheimer’s Disease Trial

Publication title: “Oral Blarcamesine Phase IIb/III Trial Confirms Identified Precision Medicine Patient Population – Significant Broad Clinical and Quality of…

4 months ago

Cellectar Biosciences Presented Compelling Data in Oral Session and Panel Discussions at the American Association for Cancer Research Special Conference on Discovery and Innovation in Pediatric Cancer

CLOVER-2 Phase 1 Clinical Study Evaluating Iopofosine I 131 in Relapsed/Refractory Pediatric High-Grade Glioma Patients Showed Extended Progression-Free Survival and…

4 months ago

gammaCore® Non-Invasive Vagus Nerve Stimulation (nVNS) as an Adjunctive Treatment Associated with Improvements in Persistent Post-Concussion Symptoms

ROCKAWAY, N.J., Sept. 30, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today…

4 months ago

Kynexis Announces First Patient Dosed in Phase 2 Clinical Trial of KYN-5356 for Cognitive Impairment Associated With Schizophrenia

Based on previously reported positive Phase 1 results, Kynexis is advancing KYN-5356, a first-in-class KAT-II inhibitor, into a Phase 2…

4 months ago

BrainCo Empowers Quan to Share His “Life Without Limits”

BOSTON, Sept. 30, 2025 /PRNewswire/ -- BrainCo holds that the true value of technology lies in expanding the boundaries of…

4 months ago

Natus Acquires Holberg EEG, Expanding Innovation in Neurodiagnostic AI Solutions

MIDDLETON, Wis., Sept. 30, 2025 /PRNewswire/ -- Natus Medical Incorporated, the largest global pure-play neurodiagnostics company, today announced it has…

4 months ago